Champion Industries, Inc. CHMP
0.02 USD 0.00 (+0.00%)
At closeNov 4, 2026, 4:00 PM EST
0.0001 Day range 0.0001
0.0001 52-week range 0.02
- YTD
- 0.00%
- 1 year
- +19,900.00%
- Market cap
- 1.13K
- EPS (ttm)
- -0.03
- YTD return
- 0.00%
- 1-year return
- +19900.00%
- Volume
- 51
- Open
- 0.0001
- Previous close
- 0.02
- Day's range
- 0.0001 – 0.0001
- 52-week range
- 0.0001 – 0.02
2Y +0.0199 (+19900.00%)
Financials — quick view
CHMP Revenue — quarterly 15.87M
CHMP Net income — quarterly -81.25K
CHMP EPS — quarterly -0.01
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jun 14, 2016 | Apr 1, 2016 | 0.00 | -2.00 | — | — |
| Mar 16, 2016 | Jan 1, 2016 | 0.00 | -4.00 | — | — |
News
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC) 
Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights 
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata 
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis 
Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy 
US Stock Futures Face Dismal Day Again
Your note
Sign in to keep a note on CHMP — it syncs with the Stock Master app.